{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-011470","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.830999+00:00","generated_at":"2026-05-31T11:14:40.233019+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Xilio Q2 net loss $13.9M; initiates Phase 2 for XTX101 in MSS CRC","bullets":["Net loss $13.9M in Q2 2024 vs $19.4M in Q2 2023; R&D expenses $11.2M.","Cash and equivalents $74.9M at June 30, 2024 (up from $44.7M Dec 2023); runway into Q2 2025.","Initiated Phase 2 trial of XTX101 + atezolizumab in MSS CRC; data expected Q4 2024.","Phase 1B dose expansion for XTX301 started; Phase 1A dose escalation ongoing with no DLTs.","Promoted Chris Frankenfield to CFO while continuing as COO."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-011470","json":"https://secwatch.observer/filing/0001558370-24-011470.json","markdown":"https://secwatch.observer/filing/0001558370-24-011470.md","text":"https://secwatch.observer/filing/0001558370-24-011470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024011470/0001558370-24-011470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024011470/xlo-20240808x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:14:40.233019+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}